Table 6.
Risk factors for the presence of liver fibrosis at the last visit, corresponding to the visit at 60 months, using chi-square tests and non-parametric Mann Whitney U-tests.
| Risk factors for liver fibrosis | Liver fibrosis (APRI >0.5) | p -value | Liver fibrosis (Fib-4 ≥1.45) | p -value |
|---|---|---|---|---|
| HIV-HBV/positive HBsAg | 10 (16.7%) | 0.254 | 8 (13.3%) | 0.646 |
| HIV-HBV/negative HBsAg | 5 (13.2%) | 5 (12.8%) | ||
| HIV monoinfection | 9 (8.3%) | 10 (9.1%) | ||
| Male gender (%) | 8 (33.3%) | 0.030 | 16 (69.6%) | 0.103 |
| Median CD4 T cell count, IQR (cells/mm3) | 512 (226, 623) | <0.001 | 552 (369, 676) | 0.010 |
| CD4 T cells <200 cells/mm3 (%) |
3 (13.6%) | 0.010 | 1 (4.5%) | 0.445 |
| CD4 T cells <500 cells/mm3 |
10 (45.5%) | 0.023 | 9 (40.9%) | 0.088 |
| Log10 HIV RNA (copies/ml) | 1.65 (1.33, 4.6) | 0.119 | 1.51 (1.32, 3.11) | 0.675 |
| Detectable Plasma HIV RNA | 10 (50%) | 0.261 | 9 (50%) | 0.306 |
| Serum cholesterol (mg/dl) | 180 (137, 200) | 0.020 | 178 (146, 220) | 0.039 |
| Serum tryglicerides (mg/dl) | 108 (72, 139) | 0.018 | 121 (94, 200) | 0.655 |
| Non-Adherence to ART (%) | 6 (31.6%) | 0.006 | 6 (28.6%) | 0.019 |